Abstract

Irritable bowel syndrome (IBS) is a chronic relapsing gastrointestinal problem characterised by intestinal pain and associated alterations of defecation and/or bowel habit (constipation: IBS-C or diarrhoea: IBS-D).^1,2 Opioid receptors in the gut have a role in gastrointestinal motility, secretion and sensation.³ Τ Eluxadoline (Truberzi-Allergan) is a locally acting, mixed opioid receptor agonist/antagonist licensed for the treatment of IBS-D in adults.⁴ Here, we consider the evidence for eluxadoline and how it fts with current management strategies for IBS-D.